Investor Relations

Invest in Amotio

Contact Us
About AMS Building

Transforming Orthopaedic Revision Surgery

With innovative, patient-specific solutions, Amotio redefines orthopaedic revision surgery by making bone cement removal safer and more efficient.

Our mission is to improve surgical outcomes, restore mobility, and reduce the burden on healthcare systems worldwide. Amotio believes that every patient deserves a more precise, less invasive revision procedure — and every surgeon deserves tools that make this possible.

A Personalised Approach to Complex Surgery

Our core technology centres around the rapid and effective removal of bone cement, a critical challenge in revision hip, shoulder, and knee surgeries. By combining advanced pre-operative imaging, patient-specific planning, and personalised surgical guide creation and accurate cutting devices, we enable surgeons to work more precisely and confidently.

  • • Minimises bone loss
  • • Reduces operating time
  • • Supports faster recovery

Meeting a Global, Growing Need

The joint replacement market is expanding rapidly with the aging population and increased demand for mobility worldwide.

  • Patient Impact:
    • In the UK, 2.8 million are economically inactive due to long-term health issues, with musculoskeletal disorders ranking as the second leading cause
    • Globally over 5 million aged 50+ expected to undergo joint replacement each year
  • Global Demand:
    • By 2030, the global population aged 60+ will reach 1.4 billion
    • 50+ age group forms the largest beneficiary of joint implants
    • OECD countries: 174 procedures per 100,000 avg. for hip replacement
    • 110,000+ primary hip replacements annually (England & Wales)
  • Growth from 2010's:
    • UK: 129% increase projected by 2030
    • USA: >200% projected rise by 2030
    • Australia: 134% projected rise by 2030
    • Germany: 29% projected rise by 2040
4–10%
of implants require revision surgery
Revision can occur up to 3x per patient
21–22%
of hip revisions require re-revision surgery within 3–15 years
Musculoskeletal Research Unit, Bristol 2022
€17.5B
Global major joint implant market (projected)

With increasing volumes, revision surgery remains technically demanding, costly, and high-risk. Amotio addresses this unmet need with a unique, clinically validated approach, positioning us for rapid adoption and significant market growth.

Partnerships & Support

Building with World-Class Partners

We collaborate with leading institutions, surgeons, and healthcare innovators across Europe and the UK. Amotio's partners include UMC Utrecht and Orthopaedic Research UK, as well as support from Welsh Government and Innovate UK. These relationships strengthen our clinical credibility and accelerate our journey to market.

UMC Utrecht Orthopaedic Research UK Innovate UK Welsh Government

Funding & Financials

Backed for Growth

£1.6 million raised to date

Amotio has secured significant support from leading investors including the Development Bank of Wales, Orthopaedic Research UK, NLC Health Ventures, and key private investors. These funds enable us to advance R&D, complete critical clinical evaluations, and prepare for regulatory approval and market launch.

July 2025: Pre-Seed Closed Seed Round Preparation Underway

Team & Leadership

Experience That Drives Innovation

Our leadership team combines decades of expertise in healthcare delivery, medical device development, and commercial strategy. Supported by expert engineers, clinical advisors, and industry mentors, Amotio is building a company grounded in expertise and driven by patient-centred impact.

Board & Governance

Daniel Bee
Daniel Bee
Company Chairman
Record of building market-leading life science, diagnostics, digital health and medical device businesses across EMEA, Japan and the USA.
Directed international teams and led multiple funding rounds, acquisitions and exits for high-growth, venture-backed companies.
Iestyn Foster
Iestyn Foster
CEO & Co-Founder
35+ years in surgery, anaesthesia, and MedTech innovation.
Kim High
Kim High
Board Observer
Venture Partner with 15+ years in global healthcare.
Leads OrthoSpine & Surgery business at NLC Health Ventures.
Joane Phoenix
Dr. Joane Phoenix
Board Observer
20 years experience helping technology-based businesses grow and secure funding.
Board member at Development Bank of Wales, Technology Venture Investments team.

Milestones & Roadmap

Focused on Delivering Impact

✓ Early Milestones
  • Technology proof of concept
  • Successful prototype development
  • Surgeon-led evaluations
→ Next Steps
  • First-in-human studies
  • Regulatory submissions
  • Scale up manufacturing
Our Vision
  • Commercial launch in 2 years
  • Expansion across UK & EU
  • Global rollout

Regulatory & Quality

Committed to the Highest Clinical and Regulatory Standards

Amotio is progressing towards UKCA, EU MDR and FDA certification, with a comprehensive regulatory strategy in place. Our robust quality management values align with ISO 13485 standards, ensuring that every aspect of our product development prioritises safety, compliance, and clinical efficacy.

ESG & Impact

Improving Lives, Supporting Communities

Beyond transforming surgery, Amotio is committed to making a wider impact. By creating high-value jobs and supporting local communities, we aim to build a sustainable business that benefits patients, healthcare systems, and society. Amotio is driven by the belief that better surgical solutions can restore independence and quality of life for patients worldwide.

News & Updates

Stay Connected

Amotio regularly shares updates on key milestones, partnerships, and industry recognitions. Recent highlights include being named a finalist in the 2025 Allica Bank Great British Entrepreneur Awards and securing additional grant funding to accelerate development.

GBEA Award

Interested in Investing in Amotio?

We're actively seeking partners who share our mission to transform orthopaedic care. Reach out to explore opportunities to support our growth.

Contact Us